Laura Bhatt

Laura Bhatt has investigated the mTOR pathway as a target in HR+ breast cancer with endocrine resistance, contributing to understanding of the BOLERO-2 trial demonstrating that everolimus plus exemestane significantly prolongs progression-free survival compared to exemestane alone in aromatase inhibitor-resistant metastatic disease. Her research has examined biomarkers predictive of everolimus benefit in HR+ metastatic breast cancer including PIK3CA mutation, PTEN loss, and FGFR pathway alterations. She has studied mechanisms by which tumors acquire resistance to mTOR inhibition in the context of combination endocrine therapy and potential therapeutic strategies to overcome or prevent mTOR inhibitor resistance. Her translational work connects BOLERO-2 clinical findings with mechanistic understanding of mTOR pathway dependence in endocrine-resistant luminal breast cancers.